Nervous system tumors associated with familial tumor syndromes

Current Opinion in Neurology

Volumn 23, Issue 6, 2010, Pages 583-591

  Ohgaki, Hiroko ^a   Kim, Young Ho ^a   Steinbach, Joachim P ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cowden syndrome; familial tumor syndrome; glioma; Li Fraumeni syndrome; medulloblastoma; neurofibromatosis; tuberous sclerosis; Turcot syndrome

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

ASTROCYTOMA; BASAL CELL NEVUS SYNDROME; CHOROID PLEXUS TUMOR; COWDEN SYNDROME; DIFFUSELY INFILTRATING ASTROCYTOMA; DISEASE ASSOCIATION; DYSPLASTIC GANGLIOCYTOMA; EPENDYMOMA; FAMILIAL CANCER; GANGLIONEUROMA; GENE MUTATION; GLIOBLASTOMA; HUMAN; LHERMITTE DUCLOS DISEASE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MEDULLOBLASTOMA; MENINGIOMA; NERVE SHEATH TUMOR; NERVOUS SYSTEM TUMOR; NEURILEMOMA; NEUROECTODERM TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; PILOCYTIC ASTROCYTOMA; REVIEW; RHABDOID TUMOR; RHABDOID TUMOR PREDISPOSITION SYNDROME; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TUBEROUS SCLEROSIS; TURCOT SYNDROME;

CHILD; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDULLOBLASTOMA; NERVOUS SYSTEM NEOPLASMS; SIGNAL TRANSDUCTION; SYNDROME; TUBEROUS SCLEROSIS;

EID: 78649635096     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283405b5f     Document Type: Review

References (55)

1. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51-57.
2. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neuro-fibromatosis. Q J Med 1992; 84:603-618.
3. Stumpf DA, Alksne JF, Annegers JF. Neurofibromatosis. NIH consensus development conference statement. Arch Neurol 1988; 45:575-578.
4. Roach ES, DiMario FJ, Kandt RS, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14:401-407.
5. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358-5362.
6. Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol 1997; 15:2744-2758.
7. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system. Lyon: IARC; 2007.
8. Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer 2003; 98:618-624.
9. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993; 30:460-464.
10. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69:299-308.
11. Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50:282-290.
12. Janson K, Nedzi LA, David O, et al. Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 2006; 47:279-284.
13. Stamenkovic I, Yu Q. Merlin, a 'magic' linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 2010; 11:471-484.
14. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001; 91:803-808. (Pubitemid 32178648)
15. Rodriguez HA, Berthrong M. Multiple primary intracranial tumors in von Recklinghausen's neurofibromatosis. Arch Neurol 1966; 14:467-475.
16. Plank TL, Yeung RS, Henske EP. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998; 58:4766-4770.
17. Van SM, Verhoef S, Tempelaars A, et al. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J Med Genet 1999; 36:285-289.
18. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-1238.
19. Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997; 57:3245-3252.
20. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133:403-414.
21. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7:267-273.
22. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37:828-830.
23. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002; 70:829-844.
24. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9:489-499.
25. Athar M, Tang X, Lee JL, et al. Hedgehog signalling in skin development and cancer. Exp Dermatol 2006; 15:667-677.
26. Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive casesofmedulloblastoma.Br J Cancer 1991; 64:959-961.
27. Roberts CW, Orkin SH. The SWI/SNF complex: chromatin and cancer. Nat Rev Cancer 2004; 4:133-142.
28. Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 2006; 20:E11.
29. Gessi M, Giangaspero F, Pietsch T. Atypical teratoid/rhabdoid tumors and choroid plexus tumors: when genetics 'surprise' pathology. Brain Pathol 2003; 13:409-414.
30. Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999; 65:1342-1348.
31. Van Meir EG. 'Turcot's syndrome': phenotype of brain tumors, survival and mode of inheritance. Int J Cancer 1998; 75:162-164.
32. Gomez MR. Phenotypes of the tuberous sclerosis complex with a revision of diagnostic criteria. Ann N Y Acad Sci 1991; 615:1-7.
33. Shepherd CW, Scheithauer BW, Gomez MR, et al. Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study. Neurosurgery 1991; 28:864-868.
34. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol 2004; 19:643-649.
35. Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 2000; 57:662-665.
36. Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001; 23:431-436.
37. Lindstrom E, Shimokawa T, Toftgard R, Zaphiropoulos PG. PTCH mutations: distribution and analyses. Hum Mutat 2006; 27:215-219.
38. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003; 22:632-636.
39. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61:7039-7043.
40. Tucker T, Wolkenstein P, Revuz J, et al. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65:205-211.
41. Woodruff JM, Chernik NL, Smith MC, et al. Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant 'Triton' tumors). Cancer 1973; 32:426-439.
42. Louis DN, Ramesh V, Gusella JF. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 1995; 5:163-172.
43. Antinheimo J, Haapasalo H, Haltia M, et al. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 1997; 87:610-614.
44. Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001; 60:994-1003.
45. Diao JS, Xia WS, Guo SZ. Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med 2009; 361:1810-1811.
46. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008; 14:135-145.
47. Stanton BZ, Peng LF. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst 2010; 6:44-54.
48. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-1178.
49. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-574.
50. Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28:5422-5432.
51. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-498.
52. Franz DN, Krueger DA, Care MM, et al. Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS) [abstract]. J Clin Oncol 2010; 28 (Suppl):2004.
53. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63:2742-2746.
54. Ronellenfitsch MW, Brucker DP, Burger MC, et al. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 2009; 132:1509-1522.
55. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5:e8.